Testing a new injectable cancer treatment alone and with an immune therapy

Plain-English translation of NCT06022029 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called , which is injected directly into tumors to help your body fight cancer. Researchers want to find the right dose and see if it works better when combined with , an approved immune-boosting drug. The goal is to understand if this treatment is safe and effective for people with advanced cancers and lymphomas.

Currently, many people with advanced cancers don't have good treatment options left. This medication is designed to work locally where it's injected and may help your immune system recognize and fight cancer cells more effectively.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with an advanced, non-resectable, or recurrent solid tumor or lymphoma that is getting worse
you have at least one tumor that can be injected and measured on imaging
you have adequate liver and bone marrow function based on blood tests
you are willing and able to understand and sign an informed consent form

You likely don't qualify if…

you are pregnant or breastfeeding
you have had another cancer diagnosed or treated within the past 2 years (except for skin cancer or certain early-stage cancers)
you have had major surgery within 4 weeks of starting the study
you have untreated brain metastases or active infections requiring antibiotics or antivirals
you are currently enrolled in another cancer treatment trial

What participation looks like

You will receive injections of the medication directly into your tumor once a week for three weeks, then have three weeks off—and this cycle repeats. Some participants will receive the medication alone, while others will also receive (an approved immune therapy) by standard infusion every three weeks. You'll have regular blood tests and imaging scans to monitor how you're responding, and the study team will watch carefully for any side effects throughout your participation.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(16 sites)

United States

California Research Institute, Los Angeles, California

BRCR Global, Tamarac, Florida

Gabrail Cancer Center Research, Canton, Ohio

Ohio State University, Columbus, Ohio

Allegheny Health Network, Pittsburgh, Pennsylvania